Evidence map›Paper›PMID 29449529›Full record

ArticleCell death & disease2018

Gambogenic acid inhibits fibroblast growth factor receptor signaling pathway in erlotinib-resistant non-small-cell lung cancer and suppresses patient-derived xenograft growth.

Linfeng Xu, Xiaoxiao Meng, Naihan Xu, Wenwei Fu, Hongsheng Tan, Li Zhang, Qianjun Zhou, Jianan Qian, Shiwei Tu, Xueting Li and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell death & disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Traditional Chinese medicine reverses cancer multidrug resistance and its mechanism.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022
    Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Linfeng XuSchool of Pharmacy, Shanghai University of Traditional Chinese Medicine, 201203, Shanghai, P.R. China.
Xiaoxiao MengSchool of Pharmacy, Shanghai University of Traditional Chinese Medicine, 201203, Shanghai, P.R. China.
Naihan XuKey Lab in Healthy Science and Technology, Division of Life Science, Graduate School at Shenzhen, Tsinghua University, Room L410, Building L. Tsinghua Campus, 518055, Shenzhen, P.R. China.
Wenwei FuSchool of Pharmacy, Shanghai University of Traditional Chinese Medicine, 201203, Shanghai, P.R. China.
Hongsheng TanSchool of Pharmacy, Shanghai University of Traditional Chinese Medicine, 201203, Shanghai, P.R. China.
Li ZhangSchool of Pharmacy, Shanghai University of Traditional Chinese Medicine, 201203, Shanghai, P.R. China.
Qianjun ZhouShanghai Lung Cancer Center, Shanghai Jiao Tong University School of Medicine (SJTUSM), Shanghai, P.R. China.
Jianan QianShanghai Chempartner Co., Ltd, 201203, Shanghai, P.R. China.
Shiwei TuShanghai Chempartner Co., Ltd, 201203, Shanghai, P.R. China.
Xueting LiShanghai Chempartner Co., Ltd, 201203, Shanghai, P.R. China.
Yuanzhi LaoSchool of Pharmacy, Shanghai University of Traditional Chinese Medicine, 201203, Shanghai, P.R. China. laurence_ylao@163.com.ORCID 0000-0002-7803-4484
Hongxi XuSchool of Pharmacy, Shanghai University of Traditional Chinese Medicine, 201203, Shanghai, P.R. China. xuhongxi88@gmail.com.
Shanghai University of Traditional Chinese Medicine · CNShanghai Innovative Research Center of Traditional Chinese Medicine · CNShanghai Jiao Tong University · CNUniversity Town of Shenzhen · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Erlotinib resistance causes a high degree of lethality in non-small-cell lung cancer (NSCLC) patients. The high expression and activation of several receptor tyrosine kinases, such as JAK/STAT3, c-Met, and EGFR, play important roles in drug resistance. The development of tyrosine kinase inhibitors is urgently required in the clinic. Our previous study found that Gambogenic acid (GNA), a small molecule derived from the traditional Chinese medicine herb gamboge, induced cell death in several NSCLC cell lines through JAK/STAT3 inhibition. In this study, we investigated the mechanism of action of GNA in erlotinib-resistant NSCLC and patient-derived cells. The inhibition of GNA on FGFR signaling pathway was examined using biochemical kinase assays. NSCLC cell lines (HCC827, HCC827-Erlotinib-resistant, and H1650) and primary cells from patients with NSCLC with clinical resistance to erlotinib were treated with GNA, erlotinib, or their combination. Both kinase assays and cell- based assays showed that GNA inhibits the phosphorylation of multiple kinases in FGFR signaling pathway in NSCLC. The combination of GNA and erlotinib significantly attenuates the tumor growth of HCC827 and erlotinib-resistant HCC827 xenografts with low toxicity. Importantly, GNA significantly suppresses tumor growth in a lung patient-derived xenograft (PDX) model with FGFR fusion and low EGFR expression. Our findings provide preclinical evidence for using GNA as an FGFR signaling pathway inhibitor to overcome erlotinib resistance in NSCLC treatment or to enhance erlotinib efficacy when used as a combined administration.

Indexed as

Drug Resistance, NeoplasmAnimalsAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungCell Line, TumorDrug SynergismErbB ReceptorsErlotinib HydrochlorideFemaleHumansLung NeoplasmsMice, Inbred BALB CMice, NudePhosphorylationProtein Kinase InhibitorsReceptors, Fibroblast Growth FactorEGFR protein, humanErbB ReceptorsErlotinib Hydrochlorideneo-gambogic acidProtein Kinase InhibitorsReceptors, Fibroblast Growth FactorXanthenes

Identifiers

PMID29449529
PMCPMC5833807
OpenAlexW2791457809

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.